Ridaforolimus

Type: Product
Name: Ridaforolimus
First reported May 13 2014 - Updated May 13 2014 - 1 reports

IMPAKT Combination of mTOR and AKT inhibitors in patients with advanced breast cancer

A combination of mTOR inhibitor, ridaforolimus and novel AKT inhibitor, MK-2206, showed activity in heavily pretreated hormone positive and negative breast cancer patients who exhibit PI3K pathway dependence, based on low RAS signature score. The...Related ... [Published BioPortfolio - May 13 2014]
First reported Feb 28 2014 - Updated Feb 28 2014 - 1 reports

DOTW Keeps Tabs As Tax Trimming Fuels Deals

As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of the lowest effective U.S. tax rates compared to companies in other sectors. But that doesn’t mean they have stopped ... [Published The IN VIVO Blog - Feb 28 2014]
First reported Feb 25 2014 - Updated Feb 25 2014 - 1 reports

Merck Abandons Once-Promising Experimental Cancer Drug to Ariad

Merck & Co. Inc.  ( NYSE:MRK ) has officially washed its hands of a once-lauded experimental cancer drug it invested in along with Ariad Pharmaceuticals Inc.  ( NASDAQ:ARIA ) Merck informed Ariad last week that it was terminating its license agreement ... [Published Wall St. Cheat Sheet - Feb 25 2014]

Quotes

NEXT ARTICLE More From BioPortfolio on "IMPAKT: Combination of mTOR and AKT inhibitors in patients with advanced breast cancer"

More Content

All (3) | News (1) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
IMPAKT Combination of mTOR and AKT inhibitors i... [Published BioPortfolio - May 13 2014]
DOTW Keeps Tabs As Tax Trimming Fuels Deals [Published The IN VIVO Blog - Feb 28 2014]
Merck Abandons Once-Promising Experimental Canc... [Published Wall St. Cheat Sheet - Feb 25 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
DOTW Keeps Tabs As Tax Trimming Fuels Deals [Published The IN VIVO Blog - Feb 28 2014]
As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of the lowest effective U.S. tax rates compared to companies in other sectors. But that doesn’t mean they have stopped ...
Merck Abandons Once-Promising Experimental Canc... [Published Wall St. Cheat Sheet - Feb 25 2014]
Merck & Co. Inc.  ( NYSE:MRK ) has officially washed its hands of a once-lauded experimental cancer drug it invested in along with Ariad Pharmaceuticals Inc.  ( NASDAQ:ARIA ) Merck informed Ariad last week that it was terminating its license agreement ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.